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ABSTRACT
Metabolic changes are associated with cancer, but whether they are just 
bystander effects of deregulated oncogenic signaling pathways or characterize 
early phases of tumorigenesis remains unclear. Here we show in a rat model of 
hepatocarcinogenesis that early preneoplastic foci and nodules that progress towards 
hepatocellular carcinoma (HCC) are characterized both by inhibition of oxidative 
phosphorylation (OXPHOS) and by enhanced glucose utilization to fuel the pentose 
phosphate pathway (PPP). These changes respectively require increased expression of 
the mitochondrial chaperone TRAP1 and of the transcription factor NRF2 that induces 
the expression of the rate-limiting PPP enzyme glucose-6-phosphate dehydrogenase 
(G6PD), following miR-1 inhibition. Such metabolic rewiring exclusively identifies a 
subset of aggressive cytokeratin-19 positive preneoplastic hepatocytes and not slowly 
growing lesions. No such metabolic changes were observed during non-neoplastic 
liver regeneration occurring after two/third partial hepatectomy. TRAP1 silencing 
inhibited the colony forming ability of HCC cells while NRF2 silencing decreased G6PD 
expression and concomitantly increased miR-1; conversely, transfection with miR-1 
mimic abolished G6PD expression. Finally, in human HCC patients increased G6PD 
expression levels correlates with grading, metastasis and poor prognosis. Our results 
demonstrate that the metabolic deregulation orchestrated by TRAP1 and NRF2 is an 
early event restricted to the more aggressive preneoplastic lesions.
INTRODUCTION
Most neoplastic cells increase glucose utilization 
and uncouple it from oxygen availability to face hypoxic 
conditions that might occur in the core of a fast growing 
tumor mass [1]. This metabolic shift, termed aerobic 
glycolysis or Warburg effect [2, 3, 4], is also required to 
sustain the anabolic needs of tumor cells [5], mainly by 
conveying metabolites into the pentose phosphate pathway 
(PPP) that provides both biosynthetic building blocks and 
anti-oxidant defenses [6]. In parallel, mitochondria of 
tumor cells down-modulate oxidative phosphorylation 
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(OXPHOS) [7] and enhance glutamine catabolism to fuel 
essential metabolic reactions, such as the tricarboxylic 
acid (TCA) cycle [8].
Although the precise mechanisms responsible for 
the complex rewiring of these circuitries remain poorly 
understood, several signaling molecules constitutively 
deregulated in tumors, such as the PI3K/Akt/mTOR 
pathway [9], p53 [10], HIF-1α [11] and Myc [12] 
directly promote OXPHOS down-modulation and 
increased utilization of both glutamine and glucose. 
Moreover, inhibition of miR-1 following induction 
of the transcription factor NRF2 and accumulation of 
glycolytic intermediates increase PPP activity [13, 14]. 
Tumor cells exploit several strategies to inhibit rate-
limiting glycolytic enzymes: pyruvate formation is 
controlled by enhanced expression of the pyruvate kinase 
enzyme M2 (PKM2) [15]; phosphofructokinase 1 (PFK1) 
is inhibited either by induction of the fructose-2,6-
bisphosphatase TP53-inducible glycolysis and apoptosis 
regulator TIGAR [16], or by increasing intracellular 
levels of citrate, a PFK1 allosteric inhibitor [17]. Citrate 
also contributes to down-regulation of mitochondrial 
OXPHOS by inhibiting succinate dehydrogenase (SDH), 
the complex II of the respiratory chain [17]. In some 
tumor types OXPHOS is also inhibited by increased 
expression of TRAP1, a mitochondrial molecular 
chaperone of the Hsp90 family [18] that down-regulates 
both respiratory complex IV [19] and SDH [20]. SDH 
inhibition prompts accumulation of succinate and the 
ensuing activation of the transcription factor HIF-1α 
[21]. In this scenario, succinate acts as an oncometabolite 
[22], implying that metabolic changes elicited by TRAP1 
directly contribute to tumor growth [18].
In spite of these observations, key questions on the 
significance of metabolic alterations in cancer remain 
unsolved. Indeed, most of the experiments have been 
performed either on tumor cells in vitro, where their 
metabolic features can be altered, or on xenografts of 
cancer cell lines and fully developed cancers. Thus, it 
is still unknown whether a metabolic rewiring occurs 
in the early stages of neoplastic progression. This point 
is crucial to understand if metabolic alterations drive 
the tumorigenic process or are just bystander effects of 
deregulated oncogenic signaling pathways.
To address this question, in the present study we 
utilized the well-characterized rat Resistant-Hepatocyte 
(R-H) model of hepatocarcinogenesis, in which tumors are 
initiated by the chemical carcinogen diethylnitrosamine 
(DENA) and promoted by a brief treatment with 
2-acetylaminofluorene (2-AAF) combined with partial 
hepatectomy (PH) [23]. The advantage of this model is 
that it offers the possibility to identify distinct lesions 
(preneoplastic foci, preneoplastic nodules, early and fully 
developed HCCs), at well-defined timings. Through this 
experimental model, we investigated (i) whether a shift 
from OXPHOS to glycolysis is an early event in the 
hepatocarcinogenic process; (ii) whether PPP activation 
plays a role in the onset and progression of the process and 
(iii) what are the key molecules involved in the metabolic 
reprogramming of preneoplastic lesions.
RESULTS
The switch from OXPHOS to glycolysis is a very 
early event in hepatocarcinogenesis
We investigated the metabolic features of early 
preneoplastic foci (EPF) in the RH model, characterized 
by a synchronous expansion of carcinogen-initiated 
cells that can be easily identified by preneoplastic 
markers, such as the glutathione S-transferase, placental 
form (GST-P), as early as 3-7 days after PH. Indeed, 
unlike normal hepatocytes, preneoplastic hepatocytes 
are able to rapidly divide after 2/3 PH, in the presence 
of the cytostatic environment generated by 2-AAF. EPF 
appear as small spherical lesions consisting of 15 to 
100 basophilic hepatocytes, displaying several BrdU-
positive nuclei and mitotic figures (Supplementary Figure 
S1A–S1B). Immunohistochemical analysis revealed an 
increase of both the lactate transporter MCT4 and of the 
mitochondrial chaperone TRAP1 (Figure 1A) in GST-P+ 
foci, compared to surrounding liver. Notably, in GST-P+ 
EPF, marked inhibition of SDH activity (Figure 1B) 
matched TRAP1 induction. Taken together these data 
raise the possibility that metabolic adaptations involving a 
decrease in OXPHOS activity and an enhanced glycolysis 
are early events in the hepatocarcinogenic process.
The switch from OXPHOS to glycolysis identifies 
a subset of aggressive preneoplastic lesions
A rapid expansion of EPF to a nodular stage 
takes place within a few weeks [23]. While none of 
EPF is positive for the putative progenitor cell marker 
cytokeratin-19 (KRT-19), some of them become KRT-19+ 
during their progression to a nodular stage [24]. Notably, 
although KRT-19+ nodules represent a minority of the total 
preneoplastic nodules observed 10 weeks after treatment 
with DENA, 80-90% of HCCs arising in this model are 
KRT-19+ [25, 26]. This indicates that KRT-19+ lesions 
have an advantage in the progression to malignancy, while 
KRT-19- nodules undergo spontaneous regression during 
the carcinogenic process [27].
To investigate whether the metabolic reprogramming 
observed in EPF is maintained along the carcinogenic 
process and to establish whether it involves all preneoplastic 
nodules or is unique to the most aggressive GST-P+/KRT-
19+ lesions, we performed immunohistochemistry in both 
these preneoplastic populations. Similar to EPF, a strong 
induction of both MCT4 and TRAP1 was observed in 
preneoplastic nodules, demonstrating that these metabolic 
changes accompany the progression of the tumorigenic 
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Figure 1: Induction of MCT4 and TRAP1 and inhibition of SDH in Early Preneoplastic Foci (EPF) and preneoplastic 
nodules. A. IHC on serial sections of livers from rats sacrificed 4 weeks after DENA (1 week after PH) shows staining for both MCT4 and 
TRAP1 in a GST-P+ EPF (x10). B. Histochemical reaction showing impaired SDH activity in GST-P+ EPF (arrows) (x4). C. IHC on serial 
sections of livers from rats sacrificed 10 weeks after DENA shows MCT4 and TRAP1 staining in a GST-P+/KRT-19+ nodule. Absence of MCT4 
and TRAP1 staining is observed in an adjacent GST-P+/KRT-19- nodule (dotted area, x4). D. Percentage and number of KRT-19+/MCT4+ 
and KRT-19+/TRAP1+ nodules with respect to the total amount of KRT-19+ nodules. E. Photomicrographs showing a perfect match between 
GST-P/KRT-19 induction and SDH activity inhibition in nodules (dotted areas) (x1.25). F. SQR enzymatic activity of SDH in control livers 
(CO) and GST-P+/KRT-19+ (left) or GST-P+/KRT-19- (right) nodules; when indicated, 17-AAG was added 5 min before starting recordings.
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process. Interestingly, these changes occurred exclusively in 
GST-P+/KRT-19+ nodules (Figure 1C). QRT-PCR analysis 
on laser-microdissected nodules showed that the MCT4 
increase was matched by its transcriptional induction, 
whereas that of TRAP1 occurred at a post-transcriptional 
level (Supplementary Figure S2A). Conversely, GST-P+/
KRT-19- nodules did not show any MCT4 or TRAP1 
staining (Figure 1C). Of the 395 GST-P+ nodules examined, 
only 117 were KRT-19+, but, 98% and 96% of KRT-
19+ nodules were also positive for MCT4 and TRAP1, 
respectively (Figure 1D), while no MCT4 or TRAP1 
staining was found in KRT-19- nodules (data not shown).
In line with what observed in EPF, TRAP1 
induction matched inhibition of SDH activity only in 
preneoplastic GST-P+/KRT-19+ nodules (Figure 1E). 
Indeed, treatment with 17-AAG, a Hsp90/TRAP1 
inhibitor that can be used as a bona fide selective TRAP1 
inhibitor when measuring SDH activity [21], doubled 
SDH activity; SDH activity of GST-P+/KRT-19- nodules 
was identical to that of normal liver, and 17-AAG was 
ineffective (Figure 1F). Moreover, a strong HIF-1α 
staining was observed only in preneoplastic GST-P+/KRT-
19+ nodules (Supplementary Figure S2B). These data are 
in agreement with our previous observations showing 
that in tumor cells TRAP1 causes SDH inhibition, and 
the consequent rise in intracellular succinate levels 
induces HIF-1α stabilization [21]. GST-P+/KRT-19+ 
nodules also displayed a strong citrate synthase (CS) 
signal that paralleled TRAP1 induction (Figure 2A and 
Supplementary Figure S2C). Since citrate is an allosteric 
inhibitor of both PFK1 and SDH [17], enhancement of 
CS activity could play an important role in the metabolic 
rewiring of early lesions towards the inhibition of late 
glycolytic steps and OXPHOS. We therefore evaluated 
both citrate content and CS activity in macrodissected 
preneoplastic nodules and found that both were increased 
only in GST-P+/KRT-19+ lesions (Figure 2B–2C). 
Treatment with 17-AAG selectively inhibited CS activity 
in GST-P+/KRT-19+ nodules (Figure 2B–2C), suggesting 
that TRAP1 contributes to CS activation.
Metabolic reprogramming is maintained 
in advanced HCCs
Fully advanced HCCs developed 14 months 
after treatment with DENA displayed several clusters 
of hepatocytes positive for both MCT4 and TRAP1 
(Figure 2D), and an increase in TRAP1 protein levels 
in HCC, as well as in GST-P+/KRT-19+ nodules, was 
confirmed by Western blot analysis (Figure 2E). In accord 
with TRAP1 induction, a strong SDH activity inhibition 
was observed in HCC compared to the peri-tumoral tissue 
(Figure 2F). Thus, the metabolic reprogramming in very 
early stages of the neoplastic process is maintained in fully 
transformed cells, suggesting that it is a critical event in 
the progression of HCC development.
To further gain insights on the metabolic changes 
observed in hepatocarcinogenesis, HCC cells obtained 
from a HCC-bearing rat exposed to the RH protocol 
and sacrificed 14 months after DENA were compared 
to non-tumorigenic rat hepatocytes (RNT) derived from 
a rat exposed to the same protocol, with the exception 
of DENA (AAF + PH only); RNT cells did not acquire 
transformed features and maintained the normal 
hepatocyte morphology [26]. RH cells showed increased 
glycolytic activity, as they displayed an increase in the 
extracellular acidification rate (ECAR), which indicates 
enhanced lactate release following glucose administration 
(Figure 3A, left).The enhanced glycolytic activity of RH 
cells was also confirmed by their higher glucose uptake 
and lactate release and by an increase in the expression 
of both MCT4 and of the glucose transporter GLUT1, 
compared to RNT cells (Figure 3B-3C and Supplementary 
Figure S3A). In addition, the expression of Hexokinase 
II (HK II), the HK isoform highly induced in a variety 
of tumor cells [28], where it binds to mitochondria and 
contributes to cell survival [29, 30, 31], was much higher 
in RH cells than in RNT hepatocytes (Figure 3C), where 
HK II associated with mitochondria (Supplementary 
Figure S3B). In RH cells, glycolysis induction matched 
inhibition of OXPHOS, as demonstrated by decreased 
oxygen consumption rate (OCR) both in basal conditions 
and after maximal stimulation with the proton uncoupler 
carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP) (Figure 3A, right). Moreover, RH cells had a 
diminished release of radiolabeled CO2 (Supplementary 
Figure S3C) and lower uptake of lactate (Supplementary 
Figure S3D). When we performed experiments using 
radioactive lactate, we found that signal of lactate-derived 
lipids and proteins paralleled that of lactate uptake and 
CO2 production from lactate (Supplementary Figure S3E). 
This suggests that the decrease observed in the lactate-
dependent bioenergetic reactions and anabolism is due to 
the minor lactate uptake that characterizes the Warburg-
addicted RH cells.
Compared to RNT cells RH cells expressed higher 
protein levels of TRAP1 (Figure 3C), and a lower 
succinate-coenzyme Q reductase (SQR) activity of SDH, 
that could be enhanced by 17-AAG, which was ineffective 
in RNT cells (Supplementary Figure S3F). in accord with 
a central role played by TRAP1 in energy metabolism 
of tumor cells, we found that knocking-down TRAP1 
increased both basal and maximal oxygen consumption 
rate of RH cells (Supplementary Figure S4A). Moreover 
RH cells showed constitutive activation of HIF-1α 
(Supplementary Figure S4B), suggesting that TRAP1-
dependent inhibition of SDH establish a pseudohypoxic 
phenotype and play a direct role in the tumorigenic 
process. Accordingly, we found that TRAP1 silencing 
inhibited the colony forming ability of RH cells, and 
this was re-established upon addition of a membrane-
permeable succinate analogue (DMS) (Supplementary 
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Figure 2: Analysis of metabolic markers in rat preneoplastic nodules and HCC. A. IHC analysis on serial sections of liver 
nodules showing a perfect match between TRAP1, CS, G6PD and TIGAR and positivity for GST-P and KRT-19 (x4). B–C.  Analysis of 
citrate levels (top) and of CS activity (bottom) in control livers (CO) and KRT-19+ or KRT-19- nodules treated or not with 17-AAG. ***P 
<0.001, ****P <0.0001. D. Staining of MCT4 and TRAP1 in HCCs, but not in the surrounding liver (x4); right side: higher magnification 
(x20) showing heterogeneous distribution of MCT4 and TRAP1 in HCC. E. Western immunoblot analysis of TRAP1 in KRT-19+ nodules, 
HCC and control liver (CO). TOM20: loading control. F. Photomicrograph showing impaired SDH activity in HCC (x1.25).
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Figure 3: Rat HCC-derived cells (RH), unlike rat non tumorigenic hepatocytes (RNT) display high aerobic glycolytic 
activity, PPP activation and OXPHOS inhibition. A. Measurements of extracellular acidification rate (ECAR, left) or of oxygen 
consumption rate (OCR, right) on monolayers of RNT and RH cells. Addition of D-Glucose, oligomycin, 2-Deoxy-D-glucose (right) and 
of oligomycin, FCCP, rotenone, and antimycin A (left) was carried out at the indicated times. B. Enhanced uptake of [3H] glucose and 
lactate release in RH cells. C. Western immunoblots showing MCT4, GLUT1, HK II, G6PD, TRAP1 and TIGAR expression. PARP and 
SDHA: loading controls. D. Radioactive assays using [14C]-glucose labeled in position C1 or in position C6 revealed an upregulation of 
CO2 produced from PPP; *P <0.05 (top); RH cells displayed a reduced PK enzymatic activity when compared to RNT cells (bottom). Data 
represent mean ± SEM **P <0.01D (left).
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Figure S5A). Notably, TRAP1-silenced RH cancer cells 
displayed a reduced expression of both HK II and CS 
(Supplementary Figure S5B). These data, together with 
the observation that 17-AAG selectively impaired CS 
activity in GST-P+/KRT-19+ nodules (Figure 2B-2C), are 
in agreement with a role played by TRAP1 in favoring 
neoplastic progression by orchestrating both OXPHOS 
inhibition and glycolysis induction via SDH inhibition 
and CS induction.
Diversion from glycolysis to PPP is restricted 
to KRT-19+ nodules
Glucose can be diverted from glycolysis to PPP to 
supply anabolic components and anti-oxidant defenses 
to the rapidly growing tumor cells [6]. Therefore, we 
evaluated PPP induction in EPF and preneoplastic 
lesions. An increased expression of G6PD protein was 
observed in EPF, that are characterized by the absence 
of KRT-19 [24] (Figure 4A) and GSTP+-KRT-19+ 
(Figure 2A, top), but not in GSTP+-KRT-19- nodules 
(Figure 2A, bottom). Enzymatic analysis showed that a 
strong increase of G6PD activity paralleled the enhanced 
levels of G6PD mRNA in GSTP+/KRT-19+ nodules 
(Figure 4B–4C).
PPP enhancement was maintained in RH cells, as 
shown by the increased amount of CO2 production from 
glucose radiolabeled in position 1 (CO2 derived from 
both OXPHOS and PPP) subtracting that originated from 
glucose radiolabeled in position 6 (CO2 exclusively derived 
from OXPHOS) (Figure 3D, top) and corroborated by 
G6PD enhanced expression (Figure 3C). Additionally, PPP 
induction was associated with inhibition of the activity 
of the final glycolytic enzyme pyruvate kinase (PK) 
(Figure 3D, bottom).
Additionally, fructose-2,6-bisphosphatase TP53-
inducible glycolysis and apoptosis regulator (TIGAR) which 
decreases the level of fructose-2,6-bisphosphate, leading to 
inhibition of late glycolytic steps [16] and increasing glucose 
funneling into the PPP, was strongly induced in GSTP+/
KRT19+ preneoplastic nodules, HCCs and RH cancer cells 
(Figure 2A-3C and Supplementary Figure S5C), but not in 
normal liver or GSTP+-KRT-19- nodules.
PPP has a major role in ROS scavenging via 
NADPH synthesis [6]. Therefore, it has been proposed 
that enhanced PPP in neoplastic cells is required 
to support their anabolic demands and to combat 
oxidative stress [6]. To determine oxidative stress in 
early preneoplastic nodules, we labeled early nodules 
with BIAM to determine the overall amount of reduced 
proteins and found a strong positive Pearson correlation 
(rp=0.93, P < 0.0001) between KRT-19 and BIAM-
labeled proteins (Figure 4D). This suggests that PPP 
induction observed in KRT19+ lesions may be a specific 
response to oxidants in aggressive preneoplastic cell 
populations.
TRAP1 accumulation and G6PD up-regulation 
are not required for normal hepatocyte 
proliferation
Metabolic changes leading to increased G6PD 
expression are associated with a higher proliferative 
capacity of KRT-19+ preneoplastic lesions (Figure 5A). To 
determine whether induction of hepatocyte proliferation is 
sufficient per se to boost aerobic glycolysis and PPP or it is 
a feature unique to tumorigenesis, we studied the metabolic 
features of normal hepatocytes undergoing proliferation 
following 2/3 PH, an experimental model that causes 
massive hepatocyte replication. By comparing samples 
obtained 24 and 48 hours after PH (time of maximal 
DNA synthesis and of the second peak of hepatocyte 
proliferation, respectively) with quiescent liver specimens, 
we could not detect any change either in TRAP1 protein 
content (Figure 5B) or in SDH and CS enzymatic activities 
(Figure 5C–5D); moreover we observed a decrease of 
G6PD mRNA and activity (Figure 5E–5F). Analysis 
of BrdU-positive hepatocyte nuclei showed massive 
hepatocyte proliferation 24 hours after surgery, thus 
ruling out the possibility that the lack of increase of the 
examined parameters could be due to a lower number 
of proliferating cells in PH-livers compared to that of 
GST-P+/KRT19+ nodules (Supplementary Figure S6). 
These data demonstrate that a metabolic shift towards 
PPP induction and OXPHOS inhibition is not required for 
normal hepatocyte proliferation, but is characteristic of 
the tumorigenic process and takes place specifically in the 
most aggressive KRT-19+ preneoplastic lesions.
NRF2 is required for the induction of G6PD, 
the TRAP1/HIF-1α pseudohypoxic axis and 
tumorigenicity
PPP activation has recently been suggested 
as one mechanism by which deregulated NRF2/
KEAP1 signaling promotes cellular proliferation and 
tumorigenesis [32, 33]. Since the NRF2/KEAP1 pathway 
is strongly activated in EPF and GST-P+/KRT-19+ 
nodules [25, 34], we investigated whether impairment 
of the NRF2 pathway could impact on G6PD expression 
levels. To this aim silencing of NRF2 was performed in 
RH tumorigenic cells. The results shown in Figure 6A-
6B indicate that NRF2 silencing significantly decreased 
G6PD expression in RH tumorigenic cells and it was 
associated with a decrease of HK II, CS and HIF-
1α protein levels (Figure 6A); while NRF2 silencing 
did not result in decreased levels of TRAP1 mRNA 
(Supplementary Figure S7), it caused a strong inhibition 
of TRAP1 protein content (Figure 6A); this result was 
somehow anticipated by the finding that TRAP1 protein 
content is not caused by increased transcription, but 
rather to post-translational mechanisms (Supplementary 
Figure S2A). Silencing of NRF2 also resulted in an 
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Figure 4: Diversion from glycolysis to PPP is restricted to highly proliferating GST-P+/KRT-19+ nodules. A. IHC on 
serial sections of livers from rats sacrificed 4 weeks after DENA shows staining for G6PD in a GST-P+ EPF (x10). B. qRT-PCR analysis 
of G6PD mRNA in GST-P+/KRT-19+ and GST-P+/KRT-19-nodules. Gene expression is reported as fold-change relative to age-matched 
controls; ***P <0.001, NS: not significant. C. G6PD activity in GST-P+/KRT-19+ and GST-P+/KRT-19-nodules compared to controls; 
*P <0.05. D. Total lysates of 11 preneoplastic nodules were BIAM labeled and subjected to WB for KRT-19 or HRP-streptavidin. 
Streptavidin and KRT-19 signals were normalized to GAPDH expression and a correlation scatter plot generated. Statistical analysis 
revealed a positive correlation between Streptavidin signal (i.e. amount of reduced protein) and KRT-19 positivity.
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Figure 5: G6PD activity is not required for normal hepatocyte proliferation. A. G6PD expression and BrdU incorporation 
in GST-P+/KRT-19+ nodules (x4). Inset; higher enlargement showing BrdU+ nuclei (x10). B. WB showing TRAP1 expression in quiescent 
and regenerating livers after 2/3 PH. TOM20: loading control. SDH (C) and CS (D) activities were assessed in control and regenerating 
liver post-PH; when indicated, samples were treated with 17-AAG. E. qRT-PCR analysis of G6PD mRNA in rats subjected to 2/3 PH 
and sacrificed 24 and 48 hours post-surgery. Gene expression is reported as fold-change relative to livers removed at the time of surgery; 
**P <0.01. F. G6PD activity in control and regenerating livers; *P <0.05.
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Figure 6: NRF2 modulates G6PD and miR-1 expression. A. Top. WB showing inhibition of G6PD, HK II, TRAP1, CS and HIF-
1α expression upon NRF2 silencing. Vinculin and SDHA: loading controls. Bottom. Immunoprecipitation assay showing an increase of 
the reduced form of PKM2 following NRF2 silencing in RH cells. B. qRT-PCR analysis of NRF2, G6PD and miR-1 RNA levels in RH 
cells upon NRF2 silencing. Values are reported as fold-change relative to cells transduced with a control shRNA. C. Radioactive assay 
using [14C]-glucose labeled in position C1 or in position C6 revealed a decrease in CO2 produced from PPP in RH cells silenced for NRF2 
(shNRF2) **P <0.01. D. Soft agar tumorigenesis assays in RH cells following NRF2 silencing. Data indicate the total colony area at the 
25th experimental day **P <0.01. E. qRT-PCR analysis of miR-1 expression in KRT-19+ nodules. Expression is reported as fold-change 
relative to age-matched controls; **P <0.01. F. qRT-PCR and WB analysis of G6PD expression in RH cells transfected with pre-miR-1.
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increase of the reduced (less active) form of PKM2 
(Figure 6A), and an impairment in the amount of 
glucose diverted into the PPP (Figure 6C). Therefore, 
NRF2 silencing causes inhibition of the TRAP1/
HIF-1α pseudohypoxic axis and of glucose funneling 
into the PPP. These changes strongly impact on cell 
tumorigenicity, as shown by soft agar growth inhibition 
of NRF2-silenced RH cells (Figure 6D).
miR-1 is involved in NRF2 induced activation 
of the PPP pathway
In agreement with recent findings proposing that 
NRF2 indirectly induces G6PD expression by down-
regulating miR-1 [33], microarray analysis performed in 
microdissected preneoplastic KRT-19+ nodules showed 
an inverse correlation between miR-1 and its target 
gene, G6PD, (Supplementary Figure S8A). Comparable 
results were obtained by qRT-PCR validation analysis 
(Figure 6E). Accordingly, in NRF2-silenced RH cells, we 
observed an increased expression of miR-1, paralleled by 
G6PD down-regulation (Figure 6B). Conversely, RH cells 
transfected with pre-miR-1 showed a significant decrease 
of G6PD mRNA and protein levels (Figure 6F).
G6PD expression is increased in human HCC
Having shown induction of G6PD and miR-1 
down-regulation in both preneoplastic and neoplastic rat 
hepatocytes, we wished to determine whether these results 
could be of translational value for human HCC. Since it 
was not possible to collect a significant number of human 
early dysplastic lesions and in consideration of the finding 
that miR-1 and G6PD expression were dysregulated all 
throughout the rat carcinogenic process, we determined 
miR-1 expression and G6PD mRNA levels in a cohort of 
59 patients subjected to liver resection for HCC (study 
population characteristics are described in Supplementary 
Table S1A). Similarly to what observed in rats, qRT-PCR 
analysis showed a significant down-regulation of miR-1 
levels (Supplementary Figure S8B) (P <0.05) in 78% of 
HCCs, when compared to matched non-cancerous liver 
cirrhotic (LC) tissues. In agreement with the decreased 
miR-1 levels, we observed a concomitant increase of 
G6PD expression in the same human HCCs compared to 
LC (P <0.05) (Figure 7A). Higher G6PD expression was 
significantly associated to high-grade (Edmonson III-IV), 
aggressive tumors (P <0.05) (Figure 7B). No difference 
was observed between LC and non-cirrhotic liver (data 
not shown).
To validate these data, we analyzed G6PD mRNA 
levels in a confirmatory independent cohort of 59 human 
HCCs and in the surrounding peritumoral tissues (study 
population characteristics are described in Supplementary 
Table S1B). Microarray analysis performed on liver 
biopsies obtained from patients carrying HCC confirmed 
a significant G6PD up-regulation in most of the tumors 
when compared to their peritumoral counterpart (P <0.05) 
(Figure 8A). Again, a higher G6PD expression was 
significantly associated to high-grade (Edmonson III-IV) 
aggressive tumors (P <0.05) (Figure 8B). Stratification 
of patients according to their etiology did not reveal any 
significant association with G6PD levels (Supplementary 
Figure S8C). Finally, to explore whether G6PD expression 
is associated with clinical progression and outcome, 
we examined the incidence of metastases and patient 
overall survival rates using Kaplan-Maier analysis. The 
metastatic status was defined as either regional lymph 
node invasion and/or distant organ involvement. High 
G6PD expression significantly correlated with metastasis 
formation (P <0.05) (Figure 8C) and decreased overall 
survival (median 35- and 11 months in low and high 
G6PD expressors), respectively (P =0.0173) (Figure 8D).
Notably, in both the cohorts a statistically significant 
increase of mRNA levels of NQO1, a well established 
NRF2-target gene, was found in HCC compared to 
cirrhotic peritumoral tissues. A significant positive 
correlation with the levels of G6PD mRNA was also 
observed in HCCs samples from patients subjected to 
liver resection (Figure 7C) or liver biopsies (Figure 8E). 
Furthermore, based on the strong link between KRT-19 
expression and G6PD throughout HCC genesis in the 
rat model, we evaluated in the Bologna cohort of human 
HCC whether KRT-19 mRNA levels could be associated 
to G6PD expression. As shown in Figure 7D, a highly 
significant correlation between KRT-19 and G6PD (P< 
0.001) was found between these two molecules.
DISCUSSION
While a complex metabolic rewiring, mainly 
towards an enhanced glucose and glutamine utilization and 
a decrease in OXPHOS, has been shown in several types 
of cancer cells and is considered a hallmark of cancer 
[35, 36], it remains unknown whether it has a key role in 
the early stages of the tumorigenic process or is simply 
a bystander event of deregulated oncogenic signaling in 
fully transformed cells.
A novel finding of the present work is that this 
metabolic switch is a very early change, as it occurs 
concomitantly with the clonal expansion of carcinogen-
induced “initiated” hepatocytes observed within few days. 
Notably, this metabolic reprogramming is selectively 
maintained only in KRT-19+ nodules that are considered 
the precursor lesions of HCC in this experimental model, 
and is exclusively associated to tumorigenesis and not 
merely linked to the entry into the cell cycle of normal 
hepatocytes. Interestingly, not all the cells within the 
nodules are homogeneously stained. This is particularly 
true for CS, TIGAR and TRAP1. Although, at the 
present it is not possible to fully appreciate the reason of 
this heterogeneity, this finding is expected as it clearly 
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indicates that differences in the metabolic reprogramming 
occur inside the GST-P+/KRT-19+ nodules, and these 
probably depend on several environmental factors such as 
local oxygen tension or distance from capillaries.
Interestingly, this early metabolic shift is a two-
pronged process composed of both OXPHOS inhibition 
and PPP induction. Two molecules seem to be deeply 
involved in this metabolic adjustment, TRAP1 and NRF2. 
TRAP1 is a mitochondrial molecular chaperone that is 
gaining increasing interest, as it orchestrates metabolic 
changes that influence neoplastic progression [18]. Indeed, 
TRAP1 knocking-down abolishes tumor growth both in 
in vitro assays and in xenografts [21]. Accordingly, in the 
present study TRAP1 induction was observed at all the 
stages of the tumorigenic process, namely in EPF, KRT-
19+ nodules and full-blown HCC. The findings that i) 
TRAP1 silencing decreases HK II expression and in vitro 
tumorigenesis and ii) TRAP1 decreases SDH activity, 
Figure 7: G6PD is up-regulated in human resected HCCs and correlates with NQO1 and KRT-19 mRNA levels. 
A. Average levels of G6PD expression in human resected HCCs (n=59) and their peritumoural cirrhotic liver (Liver Cirrhosis, LC; 
n=59). G6PD mRNA expression is calculated as fold change difference compared to LC. β-actin was used as endogenous control; *P 
<0.05. B. G6PD mRNA levels correlate with high-grade (Edmonson III-IV), (P = 0.04). C. Scatter-plot graphic showing a positive 
correlation between NQO1 and G6PD mRNA levels in human resected HCCs; D. Scatter-plot graphic showing an positive correlation 
between KRT-19 and G6PD mRNA levels in the same human HCCs.
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Figure 8: G6PD is up-regulated in biopsies from human HCCs and correlates with metastatic status, poor prognosis 
and NQO1 mRNA levels. A. G6PD mRNA levels in a validating cohort of biopsied human HCCs (n=59) and their peritumoural liver 
(PT). The levels of G6PD mRNA in healthy livers are also shown (left); *P < 0.05. B. Higher G6PD expression was significantly associated 
with high-grade (Edmonson III-IV, *P<0.05) and significantly correlated C. with metastasis formation; *P <0.05; D. Kaplan-Maier analysis 
showing decreased overall survival of HCC patients expressing high G6PD mRNA levels; P = 0.0173. E. Scatter-plot graphic showing a 
positive correlation between NQO1 and G6PD mRNA levels in HCC.
Oncotarget14www.impactjournals.com/oncotarget
prompting succinate accumulation and the ensuing HIF-1α 
stabilization, thus shifting the burden of ATP production 
to glycolysis [18, 21] are further indicative of a key role 
of this chaperone in the switch towards a more glycolytic, 
Warburg-like phenotype.
Additionally, TRAP1 can also have a role in reducing 
the glycolytic flux, hence inducing accumulation of 
glycolytic intermediates and their funneling into the PPP, by 
increasing CS protein level and enzymatic activity, leading 
to an increase of citrate, an important allosteric inhibitor of 
PFK1 and therefore of the late glycolytic steps [17].
The second branch of the metabolic rearrangement 
observed in the present study is the enhancement of PPP 
activity. Interestingly, both OXPHOS inhibition and the 
increased expression of G6PD, a rate-limiting enzyme in 
the PPP, were observed in EPF and in KRT-19+ nodules 
which are both characterized by a high proliferation 
rate. However, our present data demonstrate that G6PD, 
whose activity is required for providing both pentoses 
needed for the intense nucleic acid synthesis of dividing 
cells and NADPH to protect cells from increased ROS 
generation [6], is not a “per se” requirement for hepatocyte 
proliferation. Indeed, the massive hepatocyte proliferation 
observed during liver regeneration post-PH is associated 
with marked G6PD down-regulation. Thus, it is likely 
that the enhanced expression of this gene is specific for 
cells addressed to cancer progression and that the primary 
role of PPP induction is to maintain the redox equilibrium 
in preneoplastic cells, whereas pentoses can also be 
generated by the non-oxidative phase of PPP in a G6PD-
independent manner [6]. Accordingly, we recently found 
that intracellular ROS levels are increased in tumorigenic 
cells compared to the non-tumorigenic counterpart [37]. 
In this context, it should be noted that the activation of 
NRF2/KEAP1 transcriptional pathway may play a critical 
role in G6PD increase. NRF2 regulates antioxidant genes, 
thus protecting cells from excessive ROS damage and, as 
recently shown, sustained activation of NRF2 signaling 
in cancer cells attenuated miR-1 expression, leading 
to enhanced expression of PPP genes [38]. Our study 
provides support to this finding and also demonstrates 
that, in an in vivo model of hepatocarcinogenesis, miR-
1 expression is down-regulated in KRT-19+ nodules 
expressing high levels of NRF2-target genes [26]. 
Our data also show that NRF2 silencing decreased 
G6PD expression and concomitantly increased miR-1, 
while transfection with miR-1 mimic abolished G6PD 
expression. Moreover, NRF2 silencing down-modulated 
HK II, CS, TRAP1 and HIF-1α, further indicating a 
central function of NRF2 as metabolic programmer.
Remarkably, the translational value of the present 
results can be inferred by the observation that, similar to 
rat pre- and neoplastic lesions, in human HCCs high G6PD 
expression is associated with miR-1 down-regulation and 
correlates with tumor grading, metastatic status and poor 
prognosis. Finally, the relevance of these data is further 
strengthened by the concordance of the findings obtained 
in two large independent cohorts of human HCCs, made 
of either resected or liver biopsies samples.
In conclusion, the present work establishes that a 
metabolic shift characterized by impaired OXPHOS and 
increased glucose usage, mainly funneled into the PPP, is 
a very early event in hepatocarcinogenesis.
Future studies will address the question of whether 
targeting NRF2 impairs the growth of cancer cells and 
improve patients' prognosis and whether TRAP1 is 
another possible therapeutic target, as this chaperone 
might be responsible for the shift from OXPHOS to 
glycolysis.
MATERIALS AND METHODS
Animals and treatments
Guidelines for Care and Use of Laboratory Animals 
were followed during the investigation. All animal 
procedures were approved by the Ethical Commission 
of the University of Cagliari and the Italian Ministry of 
Health. Male Fischer rats (Charles River, Milano, Italy) 
were treated with a single dose of DENA (150 mg/kg) and, 
two weeks later, subjected to the RH protocol, consisting 
of a 2 weeks-diet supplemented with 0.02% 2-AAF and 
a 2/3 PH [23]. A group of animals was sacrificed 7 days 
after PH, while the remaining rats were then switched to 
basal diet and sacrificed ten weeks or fourteen months 
after DENA administration.
Cell cultures and in vitro experiments
RH and RNT cells were obtained from rats treated 
with DENA+AAF+PH (tumor bearing rats) or AAF+PH 
(rats with no tumors), respectively, as described [26]. 
Briefly, liver was perfused at 10 ml/min via portal vein 
at 37°C for 5 minutes with buffer containing 1.9 mg/ml 
EGTA, for 2 minutes with buffer lacking EGTA, and 
for 10-15 minutes with buffer containing 0.03% (w/v) 
collagenase and 5 mM CaCl2. 2H2O as originally described 
[39] with modification for rat liver. The perfusion 
buffer contained 10 mM HEPES, 3 mM KCl, 130 mM 
NaCl, 1 mM NaH2PO4.H2O, and 10 mM D-glucose, 
pH 7.4 (Sigma-Aldrich; collagenase from Worthington 
Biochemical Corp.). The livers were dissociated in 
perfusion buffer, and cells were passed through Dacron 
fabric with 80 μm pores and centrifuged under 50 x g for 
5 minutes to recover hepatocytes present in the pellet. 
For livers containing tumors, digestion continued in the 
plastic dish for an additional 10-20 min in the presence 
of collagenase: after incubation, the tumors present in the 
remaining parenchyma were mechanically disrupted. Cells 
were recovered and washed in medium several time, then 
seeded on collagen-coated plastic dish and maintained in 
RPMI 1640 medium supplemented with 10% FBS.
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RH cells were transiently transfected with 200 pmol 
of miR-1 mimic (Ambion, Austin, TX) or 200 pmol of 
siRNAs (control siRNA or NRF2 siRNA, Ambion) using 
Lipofectamine 2000 (Invitrogen, Paisley, UK). RH cells 
were stably transduced with the 217CS-SH213J-LVRH1P 
lentiviral vector containing a specific custom-designed 
NRF2 targeting short hairpin RNA (GeneCopoeia, 
Rockville, MD). Transduced cells were selected by 
treatment with puromycin (1 μg/ml for 7 days; Invitrogen).
Histology, immunohistochemistry and laser 
capture microdissection
Paraffin-embedded tissue was cut into 4 μm sections, 
dewaxed, and hydrated. Endogenous peroxide was inactivated 
using hydrogen peroxide. Slides were microwaved in 
citrate buffer pH 6.0 (Abcam), except for GST-P and 
TRAP1 staining, followed by overnight incubation with 
the primary antibodies: GSTP (MBL), KRT-19, HIF-1α 
(Novus Biologicals), MCT4, TRAP1, G6PD (Santa Cruz 
Biotechnology), CS (Abcam) and TIGAR (Millipore). After 
washes, the sections were incubated with the appropriate 
biotin-conjugated secondary antibody (Vector Laboratories) 
at room temperature. Signal was detected using the Vectastain 
ABC Elite kit (Vector Laboratories) and developed using 
3,3’-diaminobenzidine tetrahydrochloride hydrate, DAB, 
(Sigma-Aldrich). Sections were counterstained with Harris 
hematoxylin solution (Sigma-Aldrich) and passed through 
the dehydration process and covered. For negative control, 
the sections were incubated with secondary antibodies only. 
For BrdU staining four-micrometer-thick sections were 
deparaffinized, treated with 2N HCl, then immersed in 0.1% 
Trypsin (Sigma-Aldrich) and incubated sequentially with 
goat serum (Dako), mouse monoclonal anti-BrdU antibody 
(Becton Dickinson) and with Dako EnVision+® System 
Labelled Polymer-HRP anti-mouse (Dako). The sites of 
peroxidase binding were detected by DAB.
KRT-19 and GSTP staining was also performed on 
frozen tissue as follows: cryostat cut (Leica CM 1950), frozen 
liver sections were fixed in -20°C acetone or in formalin at 
room temperature. Anti-CK19 antibody (Novocastra) or anti-
GST-P antibody (MBL) were successively applied. After 
washes, the sections were incubated with the appropriate 
secondary antibodies (Sigma-Aldrich) at room temperature. 
The final reaction was visualized using DAB.
GSTP-positive, KRT-19-positive nodules were 
identified by immunohistochemical staining of 6 μm-
thick frozen liver sections. Nodule microdissection 
was performed on 16 μm serial sections with a Leica 
LMD6000, as previously described [24].
Immunoprecipitation, immunoblot analysis, 
antibodies and BIAM labeling
Cells derived from our experimental conditions were 
lysed in radioimmunoprecipitation assay (RIPA) buffer and 30 
μg of total proteins were loaded on precast SDS-PAGE gels 
(BioRad), separated and transferred onto PVDF membrane. 
Immunoblots were incubated overnight in 5% BSA or 
milk in T-PBS at 4°C and probed with primary and appro-
priate secondary Horseradish Peroxidase (HRP)-antibodies. 
Immunoprecipitation was performed on 500 mg of total 
proteins in 500 ml of RIPA buffer using 20 μl of protein A/G 
plus (Santa Cruz Biotechnology) per samples, following 
manufacturer’s instruction.
Detection of PKM2 redox state, N-(biotinoyl)-
N’-(iodoacetyl) ethylene diamine BIAM labeling was 
performed as previously described [34]. Briefly, cells 
were rapidly rinsed in liquid nitrogen and exposed 
to RIPA buffer containing 100 μM of BIAM diamine 
and incubated for 15 min at room temperature. Lysates 
were then clarified by centrifugation and 500 μg of each 
sample were suspended into 500 μl of RIPA buffer and 
immunoprecipitated using 20 μl of Streptavidin-agarose 
beads (Sigma). Immunocomplexes labelled with BIAM 
were separated by SDS–PAGE and the biotinylated/
reduced fraction was revealed with HRP-conjugated.
Antibodies
Mouse monoclonal anti TIGAR and SDHA, goat 
polyclonal anti calnexin, actin and HK II, and rabbit 
polyclonal anti PARP, MCT4, G6PD and TOM20 
antibodies were from Santa Cruz Biotechnology; rabbit 
polyclonal anti AIF and HIF1α antibodies were from 
Exalpha Biologicals and Novus Biologicals, respectively; 
rabbit polyclonal anti Citrate synthase and GLUT1 
antibodies were from Abcam; mouse monoclonal anti 
GAPDH and TRAP1 antibodies were from Millipore and 
Becton Dickinson, respectively.
RNA extraction and qRT-PCR
Total RNA was extracted from preneoplastic 
lesions, HCCs and RH cells with the MirVana kit (Life 
Technologies) and stored at -80°C until needed. Following 
extraction, RNA was quantified by NanoDrop ND1000 
(Thermo Scientific), while RNA integrity was assessed 
by Agilent Bioanalyzer 2100. Only RNA samples with a 
RIN (RNA Integrity Number) ≥ 7 were included in the 
study. For HCCs and human HCC cell lines, RNA was 
extracted with RNeasy Plus Mini Kit (QIAGEN) or with 
TRIzol RNA isolation reagent (Life Technologies). RNA 
was retrotranscribed with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Life Technologies) 
using random primers. Gene expression was evaluated 
by real time PCR analysis with an ABI PRISM 7300HT 
thermocycler (Applied Biosystems) on 16 samples of 
GSTP-positive preneoplastic nodules.
Assay of intracellular reactive oxygen species (ROS)
To evaluate intracellular production of H2O2 cells 
were treated for 3 minutes with 5 μg/ml H2DCF-DA. 
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After PBS washing, cells were lysed in RIPA buffer and 
analyzed immediately by fluorimetric analysis at 510 nm. 
Data were normalized to total protein content.
Mitochondria fractionation
Mitochondria were isolated after cell disruption 
with a glass-Teflon or electrical potter (Sigma) in a buffer 
composed of 250 mM sucrose, 10 mM Tris-HCl, 0.1 
mM EGTA-Tris, pH 7.4. Nuclei and plasma membrane 
fractions were separated by mild centrifugation (700 x g, 
10 min); mitochondria were then spinned down at 7,000 x 
g, 10 min, and washed twice (7,000 x g, 10 min each). All 
procedures were carried out at 4°C.
Measurements of oxygen consumption rate 
(OCR) and extracellular acidification rate 
(ECAR)
OCR was assessed in real-time with the XF24 
Extracellular Flux Analyzer (Seahorse Biosciences), which 
allows to measure OCR changes after up to four sequential 
additions of compounds. Cells (6x104/well) were plated 
the day before the experiment in a DMEM/10% serum 
medium; experiments were carried out on confluent 
monolayers. Before starting measurements, cells were 
placed in a running DMEM medium (supplemented 
with 25 mM glucose, 2 mM glutamine, 1 mM sodium 
pyruvate, and without serum and sodium bicarbonate) 
and pre-incubated for 1 hour at 37°C in atmospheric 
CO2. An accurate titration with the uncoupler FCCP was 
performed for each cell type, in order to utilize the FCCP 
concentration that maximally increases OCR. Together 
with OCR measurements, values of ECAR were also 
recorded as the absence of sodium bicarbonate allows 
changes in the pH of the medium. Addition of D-Glucose 
(10 mM), the ATP synthase inhibitor oligomycin (0.8 μM), 
the glycolytic inhibitor 2-Deoxy-D-glucose (2DG, 100 
mM), the proton uncoupler FCCP (1 μM followed by 500 
nM to a final concentration of 1.5 μM), the respiratory 
complex I inhibitor rotenone (1 μM), and the respiratory 
complex III inhibitor antimycin A (1 μM) was carried out 
at the times indicated.
Pyruvate kinase (PK) activity
PK activity was measured by a double reaction 
kinetic assay. The PK-dependent conversion of PEP into 
pyruvate is followed by pyruvate conversion into lactate 
using lactate dehydrogenase (LDH), with a concomitant 
oxidation of NADH to NAD+ and a decrease in absorbance 
at 340 nm. Both reactions can be run simultaneously as a 
kinetic assay. Cells were lysed in 50 mM Tris-HCl pH 7.4, 
in the presence of protease inhibitors and degassed for 15 
min. Measurement of PK activity was performed in 500 ml 
TRAP/4 (100 mM triethanolamine, 10 μM EDTA, 16 mM 
MgSO4, pH 7.6) in the presence of 15 μl ADP 100 mM, 
15 μl NADH 10 mM, 20 μl PEP 40 mM, 1 μl LDH (Sigma 
L2500) and 10 μl of cell lysate (1 μg/ml), adjusting with 
H2O to a final volume of 1 μl. The absorbance at 340 nm 
was monitored over 20 min (ε= 6.22 mM−1xcm−1).
Succinate dehydrogenase (SDH) activity
To measure the succinate-coenzyme Q reductase 
(SQR) enzymatic activity of respiratory chain complex 
II/succinate dehydrogenase (SDH), cells or liver samples 
were homogenized with a potter in a buffer composed 
by 250 mM sucrose, 10 mM Tris-HCl, 0.1 mM EGTA-
Tris, pH 7.4, Percoll 10%, protease and phosphatase 
inhibitors and, when specified, mitochondria were 
isolated as described above. Cell homogenates or 
mitochondrial enriched fractions (20-40 mg per trace) 
were used for assaying the succinate-coenzyme Q red-
uctase (SQR) activity of complex II/SDH through 
spectrophotometric recordings following the reduction 
of 2,6-dichlorophenolindophenol (DCPIP) at 600 nM 
(ε=19.1xmM-1xcm-1). Samples were pre-incubated for 10 
min at 30°C in a buffer composed of 25 mM potassium 
phosphate pH 7.2, 20 mM sodium succinate, and 5 μM 
alamethicin. After the pre-incubation time, sodium azide 
(5 μM), antimycin A (2 μM), rotenone (2 μM) and DCPIP 
(50 μM) were added for 1 min to the medium. Reaction 
was performed at 30°C and started after the addition of an 
intermediate electron acceptor (Coenzyme Q1, 65 μM). 
Values were then normalized for protein amount.
Complex II/SDH enzymatic activity was also 
assessed histochemically on frozen tissue sections. Eight-
micrometer-thick sections were incubated at 37°C in 
incubation medium, containing 0.2 M phosphate buffer, 
sodium succinate solution, NBT solution (Sigma-Aldrich) 
and dH2O. Successively, the liver tissue was rinsed 
in physiological saline, fixed in 10% formalin-saline 
solution, rinsed in 15% alcohol and finally mounted with 
an aqueous mounting medium. As succinate was oxidized 
to fumarate the reduced form of NADH was produced, 
and the reaction was visualized by chemically reacting 
the electron acceptor with the purple salt nitro blue 
tetrazolium (NBT).
Glucose 6 phosphate dehydrogenase 
(G6PD) activity
Liver samples were pottered and lysed at 4°C in 
a buffer composed of 140 mM NaCl, 20 mM Tris-HCl 
pH 7.4, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 
in the presence of phosphatase and protease inhibitors 
(Sigma). Lysates (10 μg) were then incubated with 
glucose-6-phosphate (1 mM) and NADP+ (1.5 mM). The 
rate of NADPH formation, which is proportional to the 
G6PD activity, was measured spectrophotometrically as 
an increase in absorbance at 340 nm at 30°C. Maleimide 
(12 mM) was added as an inhibitor of 6-phosphogluconate 
dehydrogenase.
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Citrate synthase (CS) activity
To measure CS activity, citrate formation was 
spectrophotometrically determined as an increase 
in absorbance at 420 nm at 37°C in a reaction 
buffer composed of 100 mM Tris-HCl pH 8, 0.1% 
Triton X-100, 100 μM 5,5′-dithiobis-(2-nitrobenzoic 
acid) (DTNB), 300 μM Acetyl -CoA, and 500 μM 
Oxaloacetate. Samples were prepared as described in 
the assay for SDH activity.
Measurement of citrate levels
Citrate concentration was quantified with a 
coupled enzyme assay, which results in a colorimetric 
(570 nm)/fluorometric (λex = 535/λem = 587 nm) 
product, proportional to the citrate present, following 
manufacturer’s instructions (Sigma Aldrich kit MAK057). 
Briefly, samples were rapidly homogenized with 100 μl of 
the Citrate Assay Buffer (MAK057A) and then centrifuged 
(15000 x g, 10 minutes) to remove insoluble material; 
proteins were then removed with a 10 kDa MWCO 
spin filter and then samples were resuspended in Citrate 
Assay Buffer.
Radioactive assays
Radioactive assays were performed as previously 
described [34]. Briefly, glucose or lactate uptake was 
evaluated in a buffered solution (140 mM NaCl, 20 mM 
Hepes/Na, 2.5 mM MgSO4, 1 mMCaCl2, and 5 mM 
KCl, pH 7.4) containing 0.5 μCi/ml [3H] deoxy-glucose 
or [U-14C] lactate for 15 minutes at 37°C. Cells were 
subsequently washed with cold PBS and lysed with 0.1 
M NaOH. Detection of released CO2 by radioactive 
lactate and/or glucose was performed as a read out of 
OXPHOS activity when using [U-14C] glucose. PPP 
activity was evaluated by using radioactive glucose 
labeled in position 6 [6-14C] or in position 1 [1-14C]. 
14CO2 developed from [1-
14C]-glucose oxidation 
originates by the PPP or by the TCA cycle, whereas 
14CO2 released from [6-
14C]-glucose originates only 
by TCA cycle. 2 μCi [1-14C]-glucose or 2 μCi [6-14C]-
glucose were added for 1 hour to cells (two different 
plates of same sample treated in parallel). PPP CO2 
production is therefore revealed by subtracting the 
radioactive signal derived from [1-14C]-glucose to that 
of [6-14C]-glucose. Such values were then normalized 
on total cell protein content and shown as fold change. 
Each dish had a taped piece of Whatman paper facing 
the inside part of the dish wetted with 200 μL of phenyl-
ethylamine-methanol (1:1) to trap the CO2. Then 150 μL 
of 4M H2SO4 was added to cells. Finally, Whatman 
paper was removed and transferred to scintillation 
vials for counting. Radioactive signal was measured 
by liquid scintillation counting and normalized for 
protein content.
Incorporation of lactate into proteins or lipids
[U-14C] lactate was added to cell medium for 24 
hours. For protein extraction, cells were resuspended in 
20% trichloroacetic acid, placed on ice for 30 minutes and 
centrifuged. The resuspended pellet was assayed for [14C] 
labelled proteins by scintillator. For lipid extraction, cells 
were lysed in RIPA buffer and subjected to chloroform/
methanol Bligh and Dyer extraction. The organic phase 
was recovered and assayed for [14C] labelled proteins by 
scintillator
Soft agar assay
For soft agar assays cells were grown in 24 wells 
Petri dishes covered by a bottom layer composed of 
DMEM medium mixed with low melting point agarose 
(Promega) at a final concentration of 1.0%, and by a top 
layer of DMEM medium supplemented with 2% serum 
and mixed with low melting point agarose at a final 
concentration of 0.6%. Cells (1.5x104) were added during 
the preparation of the upper layer, where they remained 
embedded. Dishes were then maintained in a humidified 
atmosphere of 5% CO2-95% air at 37°C for four weeks, 
changing the medium (DMEM 2% serum) on the top of 
the two layers every 3th day. At the 30th day, dishes were 
washed in PBS and colonies were stained with Crystal 
Violet 0.005% and analyzed with ImageJ software.
Patients
Two cohorts of patients carrying HCC were 
examined. The first cohort consisted of HCC and cirrhotic 
tissues obtained from 59 consecutive patients (45 males 
and 14 females, median age ± SD: 65.2 ± 7.9, range 
49-80 years) undergoing liver resection for HCC at the 
Department of Surgery of the University of Bologna. 
Eight normal liver tissues were obtained from patients 
undergoing liver surgery for traumatic lesions (5 cases) 
or haemangioma resection (3 cases). No patient received 
anticancer treatment prior to surgery. The characteristics 
of patients are described in Supplementary Table S1. All 
patients gave written informed consent to the study, which 
was approved by the Ethics Committee of the University 
of Bologna. In the second cohort, patient’s specimens and 
clinico-pathological data were obtained from the Institute 
of Pathology, University Hospital of Basel, Switzerland. 
All patients gave written informed consent to the study, 
which was approved by the Ethics Committee of the 
University Hospital of Basel (EKKB). HCC diagnosis 
was verified by pathological examination, no anti-cancer 
treatments were given before biopsy collection. Tumor 
differentiation was defined according to Edmondson’s 
grading system. Only biopsies containing at least 50% of 
tumor cells and no necrotic area were used in this study. 
The clinico-pathologic features of these samples are 
described in Supplementary Table S1.
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Human microarray analysis
RNA for the microarray for Transcriptomic profiling 
was isolated from 59 HCC needle biopsies matched with 
their corresponding non-neoplastic liver parenchyma and 
5 normal liver donors. RNA was isolated with a Direct-
Zol RNA MiniPrep Kit (Zymo Research) including 
on-column DNAse treatment. RNA concentration was 
assessed using Quibit (Invitrogen) and RNA integrity was 
monitored on the Bioanalyzer 2100 using the RNA6000 
Chip (Agilent). 270 ng of DNAse-treated total RNA was 
subjected to target synthesis using the WT Expression 
kit (Ambion) following standard recommendations. 
Fragmentation and labelling of amplified cDNA were 
performed using the WT Terminal Labelling Kit 
(Affymetrix). Synthesis reactions were carried out using 
a PCR machine (TProfessionnalTrio, Biometra) in 0.2 
ml tubes. 85 μl cocktail (23.4 ng/ ml labelled DNA) 
were loaded on GeneChip®Human Gene 1.0ST arrays 
(Affymetrix) and hybridized for 17 hours (45°C, 60 
rpm) in the Hybridization oven 645 (Affymetrix). The 
arrays were washed and stained on the Fluidics Stations 
450 (Affymetrix) by using the Hybridization Wash and 
Stain Kit (Affymetrix) under FS450_0002 protocol. 
The GeneChips were scanned with an Affymetrix 
GeneChip Scanner 3000 7G. DAT images and CEL files 
of the microarrays were generated using the Affymetrix 
GeneChip Command Control (version 4.0). Afterwards, 
CEL files were imported into Qlucore software and Robust 
Multichip Average (RMA) normalized. Subsequently, 
principal component analysis (PCA) to discriminate 
between normal and tumour samples was applied. Quantile 
normalization and data processing were performed using 
the GeneSpringGXv11.5.1 software package (Agilent). 
The gene signature value was assessed using the BRB-
ArrayTool (v4.3.2, NIH). Ingenuity software (Qiagen, 
Hilden, Germany) was use to perform pathways analysis.
Statistical analysis
Data are expressed as mean ± standard deviation 
(SD) or mean± standard error (SEM). Analysis of 
significance was performed by Student’s t test and by One-
Way ANOVA with Bonferroni correction when necessary.
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SUPPLEMENTARY FIGURES AND TABLE
Supplementary Figure S1: Strong proliferative activity in early preneoplastic foci. A. H&E staining of basophilic foci 
developed 1 week after PH (x4). Inset: higher enlargement (x10). B. Microphotograph showing that most of nuclei are stained for BrdU 
(right) in a GSTP+ EPFs (x10). Several mitoses are present. BrdU was given in drinking water for 24 hours prior to sacrifice.
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Supplementary Figure S2: Analysis of markers of metabolic change in preneoplastic nodules. A. qRT-PCR analysis of 
MCT4 and TRAP1 in laser-microdissected GST-P+ preneoplastic nodules. Gene expression is reported as fold-change relative to age-
matched controls; *P<0.05, NS: not significant. B. Strong HIF-1α expression in a KRT-19+ nodule (x4). Inset: enlargement showing nuclear 
HIF-1α staining (x10). C. IHC analysis on serial sections of liver nodules showing an heterogeneous staining for TRAP1, CS and TIGAR 
in GST-P+/KRT-19+ nodules (x20).
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Supplementary Figure S3: RH cells display a higher glucose metabolism and a lower SDH activity than RNT cells. 
A. qRT-PCR analysis of GLUT1 mRNA levels in RNT and RH cells. Values are reported as fold-change relative to RNT cells; *P<0.05. 
B. Western immunoblots analysis of HK II expression on mitochondrial fractions of HCC derived cells (RH) and of the non-tumorigenic 
hepatocytes (RNT). Blots were probed with anti-AIF and anti-GAPDH antibodies to check for mitochondrial protein load and cytosolic 
contaminants, respectively. C. Radioactive assays using [14C]-glucose revealed an impairment of total CO2 production (i.e. OXPHOS) in 
RH cells. D. Lactate uptake in RNT and RH cells; *P<0.05. E. Radioactive signal derived from lipids and proteins obtained from [14C] 
lactate in RNT and RH cells; ***P<0.001. F. Analysis of the SQR enzymatic activity of SDH in RNT and RH cells; when indicated, cells 
were treated with the TRAP1 inhibitor 17-AAG (5 μM).
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Supplementary Figure S4: A. Measurements of oxygen consumption rate (OCR, right) on TRAP1-silenced RH cells. Addition of 
oligomycin, FCCP, rotenone, and antimycin A was carried out at the indicated times. B. WB showing lack of HIF-1α in RNT cells. CoCl2 
(200 μM, 6 hours) is used as a positive control for HIF-1α stabilization.
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Supplementary Figure S5: Knocking-down TRAP1 expression inhibits tumorigenicity and the expression of metabolic 
enzymes in RH cells. A. Soft agar tumorigenesis assays were performed in RH cells following TRAP1 silencing and in combination 
with di-methyl-succinate (DMS, 5 mM) treatment. Data indicate the total colony area at the 25th experimental day. B. Western immunoblots 
showing TRAP1, HK II and CS expression on extracts from RH cells following TRAP1 silencing. GAPDH was used as a loading control. 
C. Western immunoblots showing increased TIGAR expression in KRT-19+ nodules and HCC samples compared to control liver (CO). 
GAPDH was used as a loading control.
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Supplementary Figure S6: BrdU incorporation in hepatocyte nuclei 24 hours after 2/3 partial hepatectomy (PH). 
Microphotograph showing BrdU staining of hepatocyte nuclei (x10). BrdU (100 mg/kg) was given intraperitoneally to animals subjected 
to surgery and to controls 2 hours prior to sacrifice.
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Supplementary Figure S7: qRT-PCR analysis of NRF2 and TRAP1 mRNA levels in RH cells upon NRF2 silencing. 
Values are reported as fold-change relative to cells untransduced wt cells.
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Supplementary Figure S8: G6PD induction in early preneoplastic lesions and human HCC. A. Illumina microarray 
(RatRef-12 V1) and TaqMan Low Density Arrays were used to determine G6PD and miR-1 expression, respectively, in KRT-19+ nodules 
10 weeks after treatment with DENA. B. Changes in miR-1 and G6PD levels in human HCCs. QRT-PCR analysis of miR-1 expression 
in human resected HCCs (n=59) and their peritumoural cirrhotic liver (Liver cirrhosis, LC; n=59). miR-1 expression is calculated as fold 
change difference compared to LC. Error bars represent SEM; U6RNA was used as endogenous control; *P< 0.05. C. Stratification of 
patients according to their etiology did not reveal any significant association with G6PD levels.
Supplementary Table S1: Study population characteristics
See Supplementary File 1
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SUPPLEMENTARY TABLE 1 
 
A 
Patient characteristics, evaluation cohort 
 
Factors  Frequency(%) 
Number of patients  59  
Mean age ± SD  67.8 ± 7.7  
Etiology  HBV  18.6% 
 HCV  62.7% 
 Alcohol abuse  3.5% 
 None 15.2% 
Cirrhosis  90% 
Serum AFP > 100 ng/ml  33% 
Edmondson grade  I   1.7% 
  II   22% 
  III  67.8% 
  IV   8.5% 
Barcelona Clinic Liver Cancer 
stage 
0 1.7% 
 A 76.3% 
 B 22% 
 C 0% 
 D 0% 
  
B 
Patient characteristics, validation cohort 
 
Factors  Frequency(%) 
Number of patients  59  
Mean age ± SD  64±12  
Etiology  HBV  19% 
 HCV  22% 
 Alcohol abuse  51% 
 None 8% 
Cirrhosis  90% 
Serum AFP > 100 ng/ml  33% 
Edmondson grade  I  2% 
  II   70% 
  III  25% 
  IV   3% 
Barcelona Clinic Liver Cancer 
stage 
0 4% 
 A 28% 
 B 40% 
 C 21% 
 D 7% 
 
 
 
